Pallas Capital Advisors LLC Sage Therapeutics, Inc. Transaction History
Pallas Capital Advisors LLC
- $2.43 Billion
- Q2 2025
A detailed history of Pallas Capital Advisors LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Pallas Capital Advisors LLC holds 16,095 shares of SAGE stock, worth $147,108. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,095
Previous 20,909
23.02%
Holding current value
$147,108
Previous $173,000
15.61%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
49.9MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$47.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$46.4 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$40.9 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$25 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$19.1 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $543M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...